EPIZYME, INC. (NASDAQ:EPZM) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry Into a Material Definitive Agreement
On September13, 2017, Epizyme, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley& Co. LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (collectively, the “Underwriters”), relating to an underwritten public offering of 9,180,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). All of the Shares are being sold by the Company. The offering price to the public is $15.25 per share, and the Underwriters have agreed to purchase the Shares from the Company to the Underwriting Agreement at a price of $14.335 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,377,000 shares of Common Stock at the same price per share as the Shares.
The Shares will be issued to a prospectus supplement dated September13, 2017 and an accompanying base prospectus dated April29, 2016 that form a part of the registration statement on Form S-3 that the Company filed with the U.S. Securities and Exchange Commission (“SEC”), which became effective on April29, 2016 (File No.333-210774). The closing of the offering is expected to take place on or about September18, 2017, subject to the satisfaction of customary closing conditions.
A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the material terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares is attached as Exhibit 5.1 hereto.
Item 1.01. Financial Statements and Exhibits.
(d) Exhibits
Epizyme, Inc. ExhibitEX-1.1 2 d451801dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 9,…To view the full exhibit click here
About EPIZYME, INC. (NASDAQ:EPZM)
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.
